Bio-Rad Laboratories, a global provider of life science research and clinical diagnostics products, has improved its Liquichek quality control product portfolio with the launch of an enhanced version of its Liquichek Opiate Control.
ACD/Labs has released version 25.4 of Katalyst D2D, extending the industry-leading workflow digitalisation software beyond its original high throughput experimentation applications to support process scale-up and material characterisation in pharmaceutical development. The enhanced platform enables pharmaceutical project teams to accelerate the design-make-test-analyse cycle from discovery through to clinical trials.
Wexis has unveiled the Atomizer, a breakthrough in microtomy workflow designed to enhance section adhesion, precision, and efficiency.
OHAUS Corporation has introduced a new series of centrifuges designed for in vitro diagnostic applications, featuring natural refrigerant R290 with substantially reduced environmental impact compared to conventional cooling systems.
Azenta Life Sciences has launched 24- and 48-format cap carriers to complement its existing 96-format solution, providing clinical laboratories with flexible, scalable options for automated sample tube management across diverse applications.
ProImmune Ltd has introduced ProVE SL Self-Loading MHC Class I Monomers, a new platform designed to provide researchers with greater flexibility in antigen-specific CD8+ T cell detection studies.
Alithea Genomics has introduced MERCURIUS® Spheroid DRUG-seq, an RNA sequencing library preparation kit designed to streamline transcriptomic analysis of three-dimensional spheroid models without requiring conventional RNA extraction steps.
κλoneus Free Light Chain (FLC) kits from Spanish in vitro diagnostics manufacturer Trimero Diagnostics SL offer clinical laboratories an alternative approach for determining Bence-Jones proteinuria based on International Federation of Clinical Chemistry (IFCC) guidelines.
Cambridge-based CN Bio has launched PhysioMimix Core, an organ-on-a-chip system designed to streamline drug development workflows by integrating multiple experimental configurations within a single microphysiological platform. The release marks a significant development in reducing animal model dependency whilst improving clinical translation of preclinical data.
Amsbio has launched a comprehensive portfolio of over 30 independently developed and manufactured cytokines specifically validated for organoid culture applications. The range addresses growing demand from researchers working with stem cells and induced pluripotent stem cells (iPSCs) in development and disease modelling, precision medicine, toxicology studies, and regenerative medicine.
March 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.